share_log

Vivos Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ionic Ventures, LLC(1.8%),Ionic Management, LLC(1.8%), etc.

Vivos Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ionic Ventures, LLC(1.8%),Ionic Management, LLC(1.8%), etc.

Vivos Therapeutics | SC 13G/A：超過5%持股股東披露文件(修正)-Ionic Ventures, LLC(1.8%),Ionic Management, LLC(1.8%)等
美股SEC公告 ·  11/14 16:14

Moomoo AI 已提取核心訊息

Vivos Therapeutics, Inc., a company listed on the U.S. stock exchange, has experienced a significant change in its shareholder structure as reported in a recent filing with the Securities and Exchange Commission (SEC). The filing, an amended Schedule 13G/A, indicates that Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of Vivos Therapeutics' outstanding common stock. The amendment, dated September 30, 2024, updates the beneficial ownership information previously filed on September 24, 2024. The Reporting Persons now collectively own 83,000 shares, representing 1.8% of the company's common stock, based on 4,765,300 outstanding shares as reported in the company's prospectus supplement. This amendment serves as an exit filing for the Reporting Persons, indicating a reduction in their collective ownership stake below the five percent threshold that requires continued reporting under SEC rules.
Vivos Therapeutics, Inc., a company listed on the U.S. stock exchange, has experienced a significant change in its shareholder structure as reported in a recent filing with the Securities and Exchange Commission (SEC). The filing, an amended Schedule 13G/A, indicates that Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of Vivos Therapeutics' outstanding common stock. The amendment, dated September 30, 2024, updates the beneficial ownership information previously filed on September 24, 2024. The Reporting Persons now collectively own 83,000 shares, representing 1.8% of the company's common stock, based on 4,765,300 outstanding shares as reported in the company's prospectus supplement. This amendment serves as an exit filing for the Reporting Persons, indicating a reduction in their collective ownership stake below the five percent threshold that requires continued reporting under SEC rules.
Vivos Therapeutics, Inc.是一家在美國交易所上市的公司，最近在向證券交易委員會（SEC）提交的文件中報告了其股東結構的重大變化。該文件爲修訂版Schedule 13G/A，表明Ionic Ventures LLC、Ionic Management LLC、Brendan O'Neil和Keith Coulston被統稱爲報告人，已不再是Vivos Therapeutics超過5%流通普通股的實際擁有者。該修訂版日期爲2024年9月30日，更新了之前在2024年9月24日提交的實際擁有信息。報告人現在共持有83,000股，代表公司普通股的1.8%，基於公司招股說明書補充中報告的4,765,300股流通股。此修訂版作爲報告人的退出文件，表明其集體持股比例已降低到5%以下，符合SEC規則中需要繼續報告的條件。
Vivos Therapeutics, Inc.是一家在美國交易所上市的公司，最近在向證券交易委員會（SEC）提交的文件中報告了其股東結構的重大變化。該文件爲修訂版Schedule 13G/A，表明Ionic Ventures LLC、Ionic Management LLC、Brendan O'Neil和Keith Coulston被統稱爲報告人，已不再是Vivos Therapeutics超過5%流通普通股的實際擁有者。該修訂版日期爲2024年9月30日，更新了之前在2024年9月24日提交的實際擁有信息。報告人現在共持有83,000股，代表公司普通股的1.8%，基於公司招股說明書補充中報告的4,765,300股流通股。此修訂版作爲報告人的退出文件，表明其集體持股比例已降低到5%以下，符合SEC規則中需要繼續報告的條件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間